Targeted Therapy
Approved for: NSCLC
Biomarker: NTRK
Larotrectinib (Vitrakvi) is a FDA-approved treatment for non-small cell lung cancer (NSCLC) with neurotrophic receptor tyrosine kinase (NTRK) gene fusion.
Larotrectinib (Vitrakvi) is a FDA-approved treatment for non-small cell lung cancer (NSCLC) with neurotrophic receptor tyrosine kinase (NTRK) gene fusion.